Retro-orbital tumour was the cause of headache and neuropathic facial pain in a 31-year-old pregnant woman. The diagnosis had been overlooked as a result of a long history of migraine. There was exacerbation of the pain throughout the pregnancy, particularly in the third trimester. Pharmacological agents commonly used to manage neuropathic pain states were relatively contraindicated due to potential adverse effects on the fetus. Cognisant of such limitations imposed by pregnancy, we used multimodal therapy in an attempt to control the pain. This included morphine, paracetamol, amitriptyline, ketamine and psychological support. The management challenges are described.
The differential diagnosis of headache is broad 1 , and accurate diagnosis can be difficult in the presence of a change in the character of the headache, for example transformed migraine 2 . Change in symptomatology may reflect the development of more sinister pathology. We describe a patient who presented in the second trimester of pregnancy for management of neuropathic facial pain caused by a retro-orbital tumour. The pregnancy itself provided additional challenges, because current Australian Drug Evaluation Committee (ADEC) guidelines 3 suggest avoidance of many commonly used antineuropathic agents, due to their potential adverse fetal effects. Anaesthetists who may be consulted in the management of unusual or severe pain in pregnancy should have some familiarity with these guidelines.
CASE REPORT
A 31-year-old woman (gravida 4, para 3) was referred to our centre during the 18th week of pregnancy for management of facial pain. She described left retro-orbital "gnawing" pain, which at times made her want to "gouge her eye out". There was radiation of pain to areas supplied by the ophthalmic and maxillary divisions of the trigeminal nerve. On occasions, headaches would be precipitated by wind blowing against the supra-orbital area. She was taking a proprietary preparation of codeine and paracetamol. Other medications included prednisone, salbutamol, fluticasone and betamethasone for asthma, and ranitidine, metoclopramide and antacid for steroid-induced reflux oesophagitis.
Her past history included classic migraine, present since 20 years of age. When 26 years old, she developed blurred vision in her left eye. A diagnosis of ischaemic optic neuropathy was made, based upon computerized tomography imaging which demonstrated non-specific thickening of the optic nerve. Twelve months later she developed left-sided retroorbital pain. Subsequently, she developed pain in the area of the second division of the trigeminal nerve, and on examination was found to have left medial optic disc atrophy. Trigeminal neuralgia was diagnosed and she was given carbamazepine with some improvement in her symptoms. The same year, during her third pregnancy, the retro-orbital pain became progressively more severe, but reduced in severity in the postpartum period.
Six months prior to our involvement, she had developed progressive loss of vision in the left eye. Magnetic resonance imaging (MRI) demonstrated a mass surrounding the posterior third of the intraorbital course of the left optic nerve, extending into the left optic foramen and involving a small section of the intracranial course of the nerve. The optic chiasm and tracts were normal. The tumour was initially assessed as inoperable. Although radiotherapy was planned, it was delayed when she became pregnant.
She was married, with three children under the age of seven years. Her husband worked as an auditor but had reduced to part-time work to help her with the children, as she was having increasing difficulty coping. The family was under considerable financial stress as a result of the reduction in income. Her mother provided a large amount of support, particularly with the care of the children. She expressed fear regarding the prospect of surgery or radiotherapy to the tumour. She was particularly afraid that she might lose the vision in the other eye. There were no psychological or physiological symptoms to suggest depression. She reported supportive marital and family relationships, and a strong religious faith.
On examination, she was a pale thin woman, with mild photophobia and nausea, but no nuchal rigidity. She was afebrile and had normal haemodynamic parameters. Visual acuity in the left eye was limited to light perception. There was proptosis with a divergent squint, an afferent pupillary defect, atrophied optic disc, and poor extra-ocular movements. The corneal reflex was intact, but light touch and pinprick sensation in the cutaneous distribution of the first two divisions of the fifth cranial nerve were subjectively decreased. There was associated allodynia, but no changes in skin colour or temperature. The remainder of the neurological examination was normal. Abdominal examination revealed an 18-week uterus with normal fetal heart rate and movements. MRI findings were unchanged when compared with the previous investigation, and were consistent with a meningioma.
Following exclusion of subarachnoid haemorrhage and pre-eclampsia, initial management included admission, intravenous fluids, patient-controlled intravenous analgesia with morphine, and droperidol. This resulted in improved pain control, with admission visual analog pain scores (VAS) of 8 to 9 decreasing to 2 to 3 (0 to 10). Subsequently, she was commenced on a sustained release oral morphine preparation at a dose of 60 mg twice a day, with morphine elixir for breakthrough pain. Our social worker was consulted and offered help strengthening home support. She was reviewed by her obstetrician and a caesarean section was planned for 34 weeks gestation.
At 23 weeks, she re-presented with uncontrolled pain; this was successfully managed by increasing her morphine to 200 mg per day. Three weeks later, she presented again with poor pain control. Regular paracetamol was commenced, and her dose of morphine was gradually increased to 360 mg per day. Under the supervision of our clinical nurse, she underwent a trial of transcutaneous nerve stimulation with application of electrodes in various positions, including frontal, parietal and upper cervical regions, but this proved ineffective. She was transferred to the obstetric unit with a view to keeping her in hospital until delivery. Psychological issues, particularly her anger at the delay in diagnosis and her concern regarding definitive treatment of the tumour, were addressed in therapy sessions with our clinical psychologist. She also participated in group therapy provided for patients requiring prolonged antepartum hospitalization.
Despite acceptable pain control following the increase in oral morphine at 26 weeks and the support from hospital admission, pain control again deteriorated at 32 weeks. Following further discussion with the patient it was decided to introduce adjuvant therapy in addition to the oral opioid. She was commenced on amitriptyline, initially 10 mg at night. This was increased over one week to 50 mg. A subcutaneous infusion of ketamine (0.1 mg/kg/h) was also introduced. This improved pain control considerably, although she reported vivid dreams and amnesia. At 33 weeks, she went into spontaneous labour and delivered a 2000 gram female infant vaginally. The neonate required 12 hours of ventilatory support, followed by 10 days in the special care nursery, but showed no evidence of opioid withdrawal.
In the post-partum period, pain was reasonably well controlled (VAS 3-4) with controlled-release morphine 150 mg three times per day. The dose of amitriptyline had been increased to 150 mg at night, and sodium valproate 200 mg three times per day was added. She occasionally required oral morphine elixir for breakthrough pain. She was referred for a second neurosurgical opinion, following which transcranial resection of the tumour revealed a mixed venous/ cavernous haemangioma. Postoperative radiotherapy was arranged and at her most recent review, although pain was still present, she felt its control was acceptable.
DISCUSSION
Primary intracranial neoplasms are rare in pregnancy, with a reported incidence of 3.6 per million births 4 . Types include gliomas, meningiomas and acoustic neuromas. Pregnancy-associated tumours such as choriocarcinoma may metastasize intra-cranially 5 . The presentation may mimic pregnancyrelated symptoms or eclampsia. Diagnosis may be delayed, particularly in the presence of other headache disorders, which have been documented to fluctuate in severity during pregnancy 6 . It is important to consider malignancy and other neurological syndromes (such as multiple sclerosis) in the differential diagnosis of trigeminal neuralgia, particularly in young women 7 .
Progression of tumour symptoms in pregnancy is well-described 5, 8 . For example, pituitary adenomas and meningiomas sometimes undergo rapid enlargement 5 . Increases in both progesterone and oestradiol throughout pregnancy may promote tumour expansion, as the majority of meningiomas have highaffinity progesterone receptors and many have oestrogen receptors 5 . In tumours without sex hormone receptors, increase in size may be due to a rise in extracellular fluid volume 8, 9 . Hormonal and physiological changes may also explain some cases that show post-partum resolution of symptoms 5 or recurrence in subsequent pregnancies 8 .
We found no reports of the management of neuropathic pain in pregnancy. Pharmacological agents which may be effective in neuropathic pain include opioids 10 , N-methyl-D-aspartate (NMDA) receptor antagonists [11] [12] [13] , antidepressants 14 , anticonvulsants 15 , clonidine 14 , topical capsaicin 14 , local anaesthetics, administered either topically or systemically, and antiarrhythmics, for example mexiletine 16 . However, many of these agents are relatively contraindicated in pregnancy due to potentially harmful effects on the fetus ( Table 1 ). The nature of these effects depends upon the timing of exposure. For example, administration from 17 to 70 days post-conception may be associated with major birth defects, whereas during the second and third trimesters, functional development may be impaired 3 .
In some cases, the benefit of a drug may exceed the risk of fetal harm. An example is anticonvulsant (Category D) therapy for epilepsy, where the risk of neural tube defects or other congenital abnormalities is thought to be outweighed by the potential for harm (to both mother and fetus) from uncontrolled seizures 3 . No similar risk-benefit analysis has been proffered with respect to the use of these and other agents for the management of neuropathic pain in the pregnant patient.
Our patient was particularly anxious not only about her tumour and its apparent progression, her poorly controlled pain and her three small children at home, but also about risk to her current pregnancy from Australian Drug Evaluation Committee Examples Classification of drugs in pregnancy Category A-have been taken by a large number of pregnant women without any proven increase in frequency of malformations or other direct or indirect harmful effects on the fetus Category B1-have only been taken by a limited number of pregnant women of women of child-bearing age without harmful effects. No evidence of fetal damage in animals Category B2-have been taken by only a limited number of pregnant women or women of child-bearing age, without an increase in harmful effects. Available animal data show no evidence of adverse effects, but data may be lacking or inadequate Category B3-have been taken only by a limited number of pregnant women and women of child-bearing age, without an increase in harmful effects. Animal studies show evidence of increased fetal damage, but significance in humans is uncertain Category C-have caused or may be suspected of causing harmful effects on the fetus or neonate without causing malformations (effects may be reversible) Category D-have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage Category X-have such a high risk of causing permanent damage to the foetus that they should not be used in pregnancy or where there is a possibility of pregnancy Not classified codeine, dextromethorphan, ketamine, lignocaine, prilocaine, paracetamol gabapentin, lamotrigine, mexiletine venlafaxine amantadine, baclofen, clonidine, flecanide morphine, methadone, oxycodone, tramadol, non-steroidal anti-inflammatory drugs (NSAIDs), clonazepam, midazolam, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) carbamazepine, phenytoin, sodium valproate capsaicin pain control treatment. We discussed other pharmacological options with her, but because of the initial sensitivity to morphine, we elected to stay with monotherapy for as long as practical. With the relatively large doses of oral morphine she had little drowsiness, but did experience nausea and constipation, both of which could have been partially attributable to her pregnancy.
The question of opioid-responsiveness of neuropathic pain is a controversial one, with some authors claiming insensitivity, and others a decreased responsiveness with shift of the dose-response curve to the right 10 . Animal models of neuropathic pain demonstrate variable responsiveness to opioids, depending upon the model and test used 17 . In patients with neuropathic cancer pain, progressive titration of opioid to either analgesia or unmanageable sideeffects results in a significant (greater than 50 per cent) pain reduction in 75 per cent of cases 10 . There is increasing evidence that different opioids have not only different side-effect profiles, but also different analgesic efficacy, possibly because some opioids have weak NMDA-receptor agonist activity 18 . An alternative strategy would have been to switch to another opioid when escalation of morphine dose failed to gain acceptable pain control. Other opioids in ADEC Category C include methadone, oxycodone and hydromorphone.
NMDA receptors are involved in the phenomenon of central sensitization 19 . NMDA receptor antagonists modify this process in both animal and human studies. Ketamine (Category A), a non-competitive NMDA receptor-antagonist, has been shown to be an effective analgesic in acute postoperative pain 20 and neuropathic pain due to cancer 11 . A double-blind trial in post-herpetic neuralgia found ketamine more effective than morphine or placebo 12 ; but it unfortunately caused side-effects in all patients. In peripheral neuropathic pain, ketamine reduces spontaneous pain and allodynia 13 , but again side-effects are limiting. Long-term subcutaneous administration may result in injection site inflammation, but poor bioavailability (approximately 20 per cent) limits its usefulness when administered orally.
Tricyclic antidepressants, in particular amitriptyline (Category C), have been shown to be effective in some neuropathic pain states 14 . These agents inhibit the re-uptake of 5-hydroxytryptamine and noradrenaline, and their analgesic action may involve enhancement of descending inhibitory pain modulation. Following delivery of our patient while awaiting definitive treatment for the tumour, a relatively high medication load was necessary despite some resolution of her pain. Management strategies for ongoing use of oral opioids in non-cancer pain have been published and we offered to share care with her family doctor and the neurosurgical team 21 .
This patient had a progressive increase in opioid requirement throughout pregnancy. In the second and early third trimesters, several episodes of increasing pain were successfully managed by increasing the morphine dose. In the final stages of pregnancy, addition of amitriptyline and ketamine resulted in significant improvement in pain control.
